Philadelphia cell and gene therapy startups: sourcing uCity Square beyond Penn
Cuts verified by word count: 40 words removed (2020 → 1980), and the title is now 64 characters. No facts, links, numbers, or sections dropped.
TITLE: Philadelphia cell and gene therapy startups: who is still active
DESCRIPTION: Philadelphia cell and gene therapy startups, mapped by deal type: which uCity Square tenants are active, which are dead, and what to verify before you call.
TAGS: biotech, deal-sourcing, united-states
Most lists of Philadelphia cell and gene therapy companies were written before the 2025 contraction, and a corp dev team working one of them in 2026 will spend its first week calling companies that no longer exist. Tmunity is inside Kite. Carisma is winding down. Spark is less than half the size it was. The campus those names came from is still one of the densest advanced-therapy clusters in the country, which is exactly why a stale roster is worse than no roster at all.
Quick answer: Philadelphia cell and gene therapy startups are concentrated in uCity Square, the University City Science Center campus around 37th and Market, which hosts 200+ science, technology and healthcare companies across 3.0M sq ft of lab and office space. For sourcing, sort the tenants by what you can do with each one (acquire the platform, license the asset, contract the manufacturing, buy the tool) and confirm a financing, lease, hiring or clinical milestone within the last 18 months before any name reaches your short list.
Why the popular Philadelphia cell and gene therapy startup lists are now a liability
The most-read roundup of Philadelphia cell and gene therapy startups is a 2020 Philadelphia magazine piece naming nine companies, and it has not been updated since. Three of those nine have materially changed state. Roche took a $2.4B full impairment on Spark Therapeutics and restructured it, with 337 layoffs beginning in May 2025, more than half the workforce. Carisma Therapeutics, a Penn spinout, cut 95% of staff, watched its OrthoCellix reverse merger fall through, and began an orderly wind-down with a voluntary Nasdaq delisting. Tmunity was acquired by Kite years ago.
Underneath those stories sits a market fact the civic-pride coverage skips. Philadelphia's University City life sciences submarket carried roughly a 39% lab vacancy rate in Q1 2026, with move-outs beating move-ins by more than 22,000 sq ft. The Chamber of Commerce for Greater Philadelphia and Econsult Solutions study that ranked the region #2 of 14 US cell and gene therapy hubs measured research infrastructure, human capital and innovation output. None of those inputs tells you whether a tenant will still hold its lease when your diligence closes.
The transferable rule: a company's appearance on a cluster list is a historical fact about publishing, not a current fact about operations. Treat every name as a hypothesis with a date attached.
What uCity Square actually contains, building by building
uCity Square is the branded redevelopment of the University City Science Center, founded in 1963 and described as the oldest and largest urban research park in the United States. The campus reports 3.0M sq ft of existing lab and office space, 200+ companies and 10,000+ researchers, with roughly 5M sq ft more approved for development. The Science Center's 2025 impact report counts 700+ startups supported since 1963, $7.6B in annual regional economic impact and 29,000 full-time jobs supported. Those are district numbers, not a tenant roster, and the campus publishes no searchable roster by company. You assemble one from leasing announcements.
| Address | Named occupants | What the address tells a buyer |
|---|---|---|
| One uCity Square | Century Therapeutics, Integral Molecular, Exponent, Charles River Laboratories; anchored by Penn Medicine's Institute for RNA Innovation and Penn Engineering's Center for Precision Engineering in Health | Over 90% leased. A mix of clinical-stage platforms, a reagents business, a CRO and a consultancy. Four different deal types in one building. |
| 3711 Market Street | Eli Lilly, Spark Therapeutics, Good Molecules | Pharma satellite space sits next to a restructured subsidiary. Neither is an acquisition target. |
| 3675 Market Street | Amicus Therapeutics' Global Research and Gene Therapy Center of Excellence; CIC Philadelphia | A corporate R&D center of excellence, plus CIC's lab hub going from 200 to over 400 benches. Bench tenants are early and often pre-incorporation. |
Read that table as a warning about resolution. An "Amicus Therapeutics" tag on the campus map is a line item in a public company's R&D budget. A bench at CIC Philadelphia is two founders and a postdoc. A leasing press release calls both uCity Square tenants.
A tenant map by deal type, not by logo
Sorting advanced-therapy tenants by what you can do with them beats sorting by science: the science rarely changes your deal structure, and stage and ownership always do. Four buckets cover the campus.
- Acquire the platform. Venture-backed, clinical or late-preclinical, independent cap table, a modality rather than a single asset. Century Therapeutics is the archetype at One uCity Square. The check here is cap-table reality: how much was raised, at what stage, and whether an existing pharma partner holds an option that forecloses a sale.
- License the asset. Companies with one program worth more than the corporate shell around it. Wind-downs and reverse-merger failures land here, which is why Carisma belongs in this column in 2026 rather than the first one. The counterparty may be a liquidating entity or the original licensor, not the company's business development team.
- Contract the manufacturing or the service. Charles River Laboratories on campus, plus the regional CDMO footprint. These are supply decisions and vendor negotiations. They never belong in an acquisition pipeline, and they show up on cluster lists constantly.
- Buy the tool. Integral Molecular is the clean example: antibody discovery and membrane-protein reagents, revenue-generating, modest capital needs, acquirable by a tools or diagnostics buyer rather than a therapeutics one.
Each bucket scores the same way we score everywhere else: relevance to the mandate, verified activity, then structural fit. The mechanics are in score acquisition targets on relevance, activity, and fit.
The activity check for a pre-revenue cell therapy company
Activity for a clinical-stage therapeutics company cannot be measured in revenue, so substitute four observable signals and require at least two inside 18 months. A financing event, priced or bridge. A clinical or regulatory milestone: IND clearance, a dose escalation, a trial readout. A real-estate action, which in this submarket means a signed or expanded lease rather than a subletted floor. And hiring, specifically process development, QA and GMP manufacturing roles, because those are the posts a company only opens when it intends to make material.
Press releases fail this test routinely. A company can publish a scientific update every quarter while its headcount falls and its sublease goes on the market. In a submarket at 39% lab vacancy, the lease signal carries more weight than it would in Cambridge, and lease-assumption risk becomes a live diligence item rather than a footnote: you may be buying a tenant whose space is worth less than its stated obligation.
Working the campus by hand against working it by mandate
Hand-assembling this map took reading seven leasing announcements, two local business-press stories, a tech-transfer blog and a vacancy report, then reconciling them against each company's own newsroom. That is a day of work for one campus, and it decays within a quarter. The alternative is to state the mandate once ("allogeneic cell therapy platforms, US Northeast, Series B or later, no exclusive pharma option") and get back the names that currently satisfy it, with the activity evidence attached. That distinction between active and merely listed is what Chibit's Innovation Scout is built to resolve, and it is the same problem we described for off-market cross-border sourcing.
Cellicon Valley companies do not all live in Philadelphia
The sharpest limitation of any address-based search is that Penn science leaves Philadelphia. Capstan Therapeutics was co-founded by Carl June and Drew Weissman, two of the people whose work defines the local cluster, and AbbVie agreed to acquire it for up to $2.1B while the company was headquartered in San Diego. A team searching "Philadelphia cell and gene therapy startups" would never have seen it.
The deals also run the other direction. Kite agreed to acquire Philadelphia-based Interius BioTherapeutics for $350M in August 2025, folding it into a Philadelphia in vivo center of excellence, its second acquisition in the city after Tmunity. So the cluster is a source of IP and founders, and only sometimes a source of corporate addresses. Source by lineage: the licensing institution, the named founder, the lab the technology came out of. Penn Center for Innovation lists its licensed spinouts and reports $1.5B+ raised by them since 2018, a better starting index than any geography filter. The general method is in find university spinout acquisition targets with this sourcing map.
Common pitfalls when sourcing this campus
Five errors account for most wasted weeks here, and all five come from mistaking a published label for an operating fact.
- Counting a corporate center of excellence as a target. Amicus's gene therapy center and Penn Medicine's RNA institute are buyers, partners and talent pools, never acquisitions.
- Treating a CIC Philadelphia bench address as a headquarters. Shared-lab tenants are often pre-Series A and sometimes pre-incorporation.
- Blending the region into the campus. Navy Yard, King of Prussia and Montgomery County are separate submarkets with separate drive times, and most Philadelphia biotech listicles merge all four. On a two-day site visit, the campus boundary matters.
- Missing a pharma option. A co-development deal with an exclusive option can make an otherwise attractive platform unbuyable, and that detail lives in an 8-K or a partner's press release rather than the company's website.
- Re-using the map without re-dating it. Re-verify financing, headcount and lease status in the week before travel. One quarter is long enough for a wind-down announcement.
FAQ
Which Philadelphia cell and gene therapy companies are still operating in 2026?
Century Therapeutics, Integral Molecular, Amicus Therapeutics and Charles River Laboratories all hold active uCity Square space as of the most recent leasing disclosures. Spark Therapeutics still occupies 3711 Market Street but was restructured after Roche's $2.4B impairment, Carisma Therapeutics is in an orderly wind-down, and Tmunity and Interius are now inside Kite. Verify each one against a financing, hiring or lease event within the last 18 months rather than against this paragraph.
How many tenants does uCity Square have?
uCity Square reports 200+ science, technology and healthcare companies and 10,000+ researchers across 3.0M sq ft of existing lab and office space. The campus does not publish a searchable tenant list by company, so a usable roster has to be assembled from individual leasing announcements and company filings.
Is "Cellicon Valley" the same thing as uCity Square?
Cellicon Valley is a nickname for the Greater Philadelphia cell and gene therapy cluster as a whole, which spans University City, the Navy Yard, King of Prussia and Montgomery County. uCity Square is one campus inside that cluster, the University City Science Center's redevelopment around 37th and Market. Treating the two as interchangeable is how site-visit itineraries end up with 40-minute drives in them.
Who should a corporate development team contact about a uCity Square tenant?
Contact the company directly for anything deal-related; the Science Center and Wexford are the campus operator and developer, and neither represents tenants in transactions. For Penn-licensed technology, Penn Center for Innovation is the counterparty on the IP and often knows the spinout's status before the market does.
What does a 39% lab vacancy rate mean for a deal?
A roughly 39% University City lab vacancy rate in Q1 2026 means space is a buyer's market, so a target's existing lease may be above market and its sublease income unreliable. Price the lease as a liability during diligence, and read an expansion or a new signed lease in that submarket as a stronger activity signal than it would be in a tight market.
To work from the current version of this map instead of the 2020 one, describe your mandate to Innovation Scout and start from a short list of companies that are active and relevant, with the evidence attached.
About Andy Chiang
Founder at Chibit
Andy Chiang is the founder of Chibit, a platform that helps corporate innovation, R&D, and M&A teams find active, relevant companies across global innovation ecosystems. He works with buyers who need short lists matched to a real mandate, not directory dumps, with particular focus on green economy, energy, and manufacturing across East Asia, North America, and Eastern Europe. Before Chibit, he spent over a decade in marketing, growth, and go-to-market for technology companies. He writes about operating leverage at Seeking Leverage and hosts Foreign Founders, a podcast and community for immigrant founders, operators, investors, and ecosystem partners. He is based in Brooklyn, New York.
You might also like
Tallinn, Estonia: the digital innovation ecosystem you can buy
The Tallinn Estonia digital innovation ecosystem has two layers: one indexed by venture databases, one that exports the digital state. Source the second.
San Marcos Texas startups: the Austin corridor's materials layer
San Marcos Texas startups cluster in materials, batteries, and diagnostics at Texas State's STAR Park. How acquirers read the roster as a sourcing filter.
South Dakota State University Research Park is not a pipeline
The South Dakota State University Research Park lists tenants, not targets. How M&A teams read a small Brookings ag-bio ecosystem directories barely cover.
Find startups relevant to your goals
Chibit surfaces active, vetted companies matched to your industry and region, so your team starts from a short list worth acting on.
Find Startups